Format

Send to

Choose Destination
Dermatology. 1995;190(2):142-4.

Treatment of verrucous carcinoma with recombinant alfa-interferon.

Author information

1
Department of Dermatology, CHRU Dupuytren, Limoges, France.

Abstract

BACKGROUND:

Verrucous carcinoma is an uncommon neoplasm whose medical treatment is not well defined.

OBJECTIVE:

We report the clinical effects of recombinant alpha-interferon (IFN) with varying dispensing routes on the tumor size in 3 patients exhibiting three different subtypes of verrucous carcinoma.

OBSERVATIONS:

In case 1, an oral florid papillomatosis of the upper gingiva, a stabilization of the lesion size was observed after the administration of a cumulative dose of 45 million IU of IFN alfa-2b. The patient died after discontinuation of the treatment due to hepatic toxicity. In case 2, a giant condyloma acuminatum of the penis, treatment with a cumulative dose of 522 million IU of IFN alfa-2a first resulted in stabilization of the disease, and no evidence of recurrence was observed after surgical treatment. In case 3, a verrucous carcinoma of the leg, a mild decrease in lesion size was observed after the administration of a cumulative dose of 174 million IU. Surgery was finally required.

CONCLUSION:

In reducing the growth of the tumor, treatment by IFN appears to be an adjuvant therapy of verrucous carcinoma, but it never prevents surgery or death.

PMID:
7727836
DOI:
10.1159/000246664
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center